Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three-arm study.
Hepatitis C
People who inject drugs
decentralized viremia testing
linkage to care
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
03
12
2021
received:
26
07
2021
accepted:
25
01
2022
pubmed:
8
2
2022
medline:
24
3
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
In 2015, Georgia began a hepatitis C virus (HCV) elimination programme. Although screening programmes have been decentralized for high-risk groups, viraemic testing remains a bottleneck for people who inject drugs. Here, we describe two models of viraemic testing that aimed to address this gap. We assigned eight harm reduction sites (HRS) to one of three arms (2,1:1): Xpert HCV viral load testing on-site, blood draw on-site with centralized HCV core antigen testing (HCVcAg), or standard-of-care (SOC) referral with viremia testing performed at treatment centres. 1671 HCV-seropositive participants were enrolled (Xpert, 37.1%; HCVcAg, 29.1%; referral, 33.8%). Participants were predominantly male (95.4%), mean age (IQR) 43 (37, 50) years and 1290 (77.2%) were currently injecting drugs. Significantly higher proportions of participants in the Xpert (100%) and HCVcAg (99.8%) arms received viraemia testing compared with the referral arm (91.3%) (Xpert vs referral, p < 0.0001; HCVcAg vs referral, p < 0.0001). Among viraemic participants, treatment uptake was similar (Xpert, 84.0%; HCVcAg, 79.5%; referral, 88.4%). The time between screening and sample collection for viraemia testing was significantly longer in the referral arm compared with both Xpert and HCVcAg arms (median 1 day compared with 0 days respectively), and the overall time between screening to treatment initiation was longer for the referral arm (median 67 days) compared with both Xpert and HCVcAg arms (median 57 and 50 days respectively). Point-of-care viraemia testing and blood drawn on-site for HCVcAg testing yielded more HCV-seropositive patients receiving viraemic testing within a shorter timeframe compared with referrals.
Sections du résumé
BACKGROUND AND AIMS
In 2015, Georgia began a hepatitis C virus (HCV) elimination programme. Although screening programmes have been decentralized for high-risk groups, viraemic testing remains a bottleneck for people who inject drugs. Here, we describe two models of viraemic testing that aimed to address this gap.
METHODS
We assigned eight harm reduction sites (HRS) to one of three arms (2,1:1): Xpert HCV viral load testing on-site, blood draw on-site with centralized HCV core antigen testing (HCVcAg), or standard-of-care (SOC) referral with viremia testing performed at treatment centres.
RESULTS
1671 HCV-seropositive participants were enrolled (Xpert, 37.1%; HCVcAg, 29.1%; referral, 33.8%). Participants were predominantly male (95.4%), mean age (IQR) 43 (37, 50) years and 1290 (77.2%) were currently injecting drugs. Significantly higher proportions of participants in the Xpert (100%) and HCVcAg (99.8%) arms received viraemia testing compared with the referral arm (91.3%) (Xpert vs referral, p < 0.0001; HCVcAg vs referral, p < 0.0001). Among viraemic participants, treatment uptake was similar (Xpert, 84.0%; HCVcAg, 79.5%; referral, 88.4%). The time between screening and sample collection for viraemia testing was significantly longer in the referral arm compared with both Xpert and HCVcAg arms (median 1 day compared with 0 days respectively), and the overall time between screening to treatment initiation was longer for the referral arm (median 67 days) compared with both Xpert and HCVcAg arms (median 57 and 50 days respectively).
CONCLUSIONS
Point-of-care viraemia testing and blood drawn on-site for HCVcAg testing yielded more HCV-seropositive patients receiving viraemic testing within a shorter timeframe compared with referrals.
Identifiants
pubmed: 35129278
doi: 10.1111/liv.15191
pmc: PMC9306782
doi:
Substances chimiques
RNA, Viral
0
Viral Core Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
775-786Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
J Viral Hepat. 2019 Jan;26(1):38-47
pubmed: 30199587
MMWR Morb Mortal Wkly Rep. 2015 Jul 24;64(28):753-7
pubmed: 26203628
Lancet HIV. 2020 Apr;7(4):e229-e237
pubmed: 32105625
Clin Infect Dis. 2020 Aug 22;71(5):1263-1268
pubmed: 31563938
J Hepatol. 2019 Oct;71(4):645-647
pubmed: 31356831
J Hepatol. 2020 Apr;72(4):680-687
pubmed: 31811882
Int J Drug Policy. 2014 Sep;25(5):871-8
pubmed: 24529802
MMWR Morb Mortal Wkly Rep. 2016 Oct 21;65(41):1132-1135
pubmed: 27764081
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
J Acquir Immune Defic Syndr. 2020 Jul 1;84 Suppl 1:S5-S11
pubmed: 32520909
J Urban Health. 2006 Mar;83(2):289-98
pubmed: 16736377
Georgian Med News. 2009 Dec;(177):51-5
pubmed: 20090154
Liver Int. 2022 Apr;42(4):775-786
pubmed: 35129278